2-[2,2-Bis(carboxymethyl)-1-oxa-4,7,10-triazacyclododec-3-yl]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[2,2-Bis(carboxymethyl)-1-oxa-4,7,10-triazacyclododec-3-yl]acetic acid
• 化学式: C₁₄H₂₅N₃O₇
• 分子量: 347.36
• InChiKey: GYKDIXWQNBFTCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.8
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  157
• 氢给体数：
  6
• 氢受体数：
  10

文献信息

• Contrast agents
  申请人：NYCOMED IMAGING AS

  公开号：US20010016587A1

  公开（公告）日：2001-08-23

  The invention provides a composition of matter of the formula (I): V—L—R where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body, with the provisos that where V is angiotensin or a peptidic angiotensin derivative or analog then V—L—R is other than a non-metal radionuclide substituted peptide (e.g. 125 I substituted angiotensin II) and L—V is other than simply a peptide with a chelating agent amide bonded to a side chain thereof. This composition of matter may be used to image cardiovascular diseases and disorders.

  本发明提供一种物质组成式(I)的组合物：V—L—R，其中V是具有与血管紧张素II受体位点结合亲和力的有机基团，L是连接基团或键，R是在人体或动物体内成像中可检测到的基团，但须注意，当V是血管紧张素或血管紧张素衍生物或类似物时，V—L—R不是非金属放射性核素替代肽（例如125I替代血管紧张素II），而L—V不是仅具有与其侧链缀合剂酰胺键合的肽。该物质组合物可用于成像心血管疾病和障碍。
• Chelants
  申请人：NYCOMED SALUTAR, INC.

  公开号：EP0481526A1

  公开（公告）日：1992-04-22

  There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a polyamine backbone molecule, e.g. polylysine. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.

  本发明提供了可用于诊断成像和放射治疗的聚螯合剂及其金属螯合物，它们由多个大环螯合剂分子（如 DOTA 残基）与多胺骨架分子（如聚赖氨酸）连接而成。为了生产定点多螯合物，可将一个或多个携带骨架的大环螯合剂分子与定点大分子（如蛋白质）连接。
• Method of imaging
  申请人：Amersham Health AS

  公开号：EP1442751A1

  公开（公告）日：2004-08-04

  The invention provides a method of generating an image of an animate human or non-human animal subject previously administered with a contrast agent involving generating an image of at least a part of said subject to which said contrast agent has distributed, characterised in that said contrast agent is a composition of matter of formula I         V - L - R     (I) where V is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker moiety or a bond and R is a detectable moiety, characterised in that V is a non-peptidic organic group, or V is peptidic and R is a macromolecular or particulate species providing a multiplicity of labels detectable in in vivo imaging.

  本发明提供了一种生成先前施用过造影剂的有生命的人类或非人类动物主体图像的方法，该方法涉及生成所述造影剂分布到的所述主体的至少一部分的图像，其特征在于所述造影剂是式 I 的物质组合物 V - L - R (I) 其中 V 是对血管生成相关内皮细胞受体具有亲和力的载体分子，L 是连接分子或键，R 是可检测分子，其特征在于 V 是非肽有机基团，或 V 是肽基，R 是大分子或微粒，可提供在体内成像中可检测的多重标签。
• Albumin fusion proteins
  申请人：HUMAN GENOME SCIENCES, INC.

  公开号：EP1997829A1

  公开（公告）日：2008-12-03

  The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. The fusion protein may comprise a hybrid (human serum albumin)/Kex2 leader sequence followed by a mature albumin fused to the N-terminus of mature interferon alpha-2b.

  本发明包括白蛋白融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。 融合蛋白可包括混合（人血清白蛋白）/Kex2前导序列，然后是与成熟干扰素α-2b的N端融合的成熟白蛋白。
• Fusion proteins of albumin and erythropoietin
  申请人：Human Genome Sciences, Inc.

  公开号：EP2277888A2

  公开（公告）日：2011-01-26

  The present invention encompasses albumin fusion proteins, namely fusions of human serum albumin and erythropoiethin. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

  本发明包括白蛋白融合蛋白，即人血清白蛋白和红细胞生成素的融合蛋白。本发明还包括编码本发明白蛋白融合蛋白的核酸分子、含有这些核酸的载体、用这些核酸载体转化的宿主细胞，以及制造本发明白蛋白融合蛋白和使用这些核酸、载体和/或宿主细胞的方法。此外，本发明还包括包含白蛋白融合蛋白的药物组合物，以及使用本发明白蛋白融合蛋白治疗、预防或改善疾病、失调或病症的方法。